[1] 孟焕新.临床牙周病学[M].北京:北京大学医学出版社, 2013:48-50.
[2] Socransky S S, Haffajee A D. Evidence of bacterial etiology: a historical perspective[J]. Periodontology 2000, 1994, 5(1): 7-25.
[3] Costerton W, Veeh R, Shirtliff M, et al. The application of biofilm science to the study and control of chronic bacterial infections[J].J Clin Inves,2003,112(10):1466.
[4] Li L X, Wang Q X, Song Z W, et al. Introduction of Biofilm with an Analysis of its Typical Process Advanced Materials Research[J]. Trans Tech Publications, 2013, 850: 1234-1237.
[5] David H, Bettina A, Rubén L, et al. Antimicrobial therapy in periodontitis: the use of systemic antimicrobials against the subgingival biofilm.[J]. J Clin Periodonto, 2008, 35(Supplement s8):45-66.
[6] Walker T S, Tomlin K L, Worthen G S, et al. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils[J]. Infection and immunity, 2005, 73(6): 3693-3701.
[7] Yu N, Oortgiesen D W, Bronckers A L J J, et al. J Clin Periodontol[J]. J Clin Periodontol, 2014, 41(6):632-632.
[8] Darveau R P, Belton C M, Reife R A, et al. Local chemokine paralysis, a novel pathogenic mechanism for Porphyromonas gingivalis[J]. Infection & Immunity, 1998, 66(4):1660-1665.
[9] Johansson A. Aggregatibacter actinomycetemcomitans leukotoxin: a powerful tool with capacity to cause imbalance in the host inflammatory response[J].Toxins,2011,3(3):242-259.
[10] Nibali L , Donos N , Farrell S , et al. Association between interleukin-6-174 polymorphism and Aggregatibacter actinomycetemcomitans in chronic periodontitis.[J]. J periodontol, 2010, 81(12):1814-1819.
[11] Darveau R P. Periodontitis: a polymicrobial disruption of host homeostasis.[J]. Nat Revi Mic,2010,8(7):481-490.
[12] Cekici A, Kantarci A, Hasturk H, et al. Inflammatory and immune pathways in the pathogenesis of periodontal disease[J]. Periodontology, 2014, 64(1):57-80.
[13] Brower V. Controlling the inflammatory cascade[J]. Dental Abstracts, 2011, 56(3):164-165.
[14] Araújo A A, Souza T O, Moura L M, et al. Effect of telmisartan on levels of IL-1, TNF-α, down-regulated COX-2, MMP-2, MMP-9 and RANKL/RANK in an experimental periodontitis model[J]. J Clin Periodontol, 2013, 40(12):1104-11.
[15] Graves D T. The potential role of chemokines and inflammatory cytokines in periodontal disease progression[J]. Clin infec Dis, 1999, 28(3): 482-490.
[16] Lane N, Armitage G C, Loomer P, et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study[J]. J periodontol, 2005,76(7):1113-1122.
[17] 陈新谦, 金有豫, 汤 光. 新编药物学[M]. 15版, 北京: 人民卫生出版社, 2002: 83-110.
[18] 张 萍, 朱聪惠, 裘松波, 等. 牙周病非手术治疗进展[J]. 中国药业, 2008, 17(3): 61-63.
[19] Lu H K, Chei C J. Efficacy of subgingivally applied minocycline in the treatment of chronic periodontitis[J]. J periodontal Res, 2005, 40(1): 20-27.
[20] 张文怡, 刘洪臣, 吴 霞, 等. 米诺环素对体外培养的成年大鼠牙槽骨成骨细胞生物活性的影响[J]. 中华老年口腔医学杂志, 2007, 5(3): 173-176.
[21] 杜华田, 曹采方. 甲硝唑棒治疗牙周炎疗效观察[J]. 牙体牙髓牙周病学杂志, 2005, 2(1): 32-34.
[22] 王凤琼, 陈晓涛, 唐柳云, 等. 西帕依固龈液治疗牙周病的临床疗效[J]. 华西药学杂志, 2006, 21(1): 109-110.
[23] 侯振伟, 白鹤翔, 张风华. 布洛芬缓释凝胶治疗慢性牙周炎的临床研究[J]. 实用口腔医学杂志, 2008, 24(5): 741-743.
[24] 王德飞. 布洛芬联合派丽奥对慢性牙周炎龈沟液中细胞因子的影响及抗氧化作用[J]. 现代预防医学, 2014, 41(6):1141-1146.
[25] Issa J P, Ingraci d L C, Bg D S K, et al. The effect of simvastatin treatment on bone repair of femoral fracture in animal model.[J]. Growth Factors, 2015, 33(2):1-10.
[26] Fracon R N, Teófilo J M, Moris I C, et al. Treatment with paracetamol, ketorolac or etoricoxib did not hinder alveolar bone healing: a histometric study in rats[J]. J Applied Oral Sci,2010,18(6):630-634.
[27] Teófilo J M, Giovanini G S, Fracon R N, et al. Histometric study of alveolar bone healing in rats treated with the nonsteroidal anti-inflammatory drug nimesulide[J]. Implant dentistry, 2011, 20(2): e7-e13.
[28] Brger U, Mühle T, Fourmousis L, et al. Effect of the NSAID flurbiprofen on remodelling after periodontal surgery[J]. J periodontal Res,1997,32(7):575-582.
[29] Coimbra L S, Rossa Jr C, Guimaraes M R, et al. Influence of antiplatelet drugs in the pathogenesis of experimental periodontitis and periodontal repair in rats[J]. J periodontol, 2011, 82(5): 767-777.
[30] Walters S M, Dubey V S, Jeffrey N R, et al. Antibiotic-induced Porphyromonas gingivalis LPS release and inhibition of LPS-stimulated cytokines by antimicrobial peptides[J]. Peptides, 2010, 31(9): 1649-1653.
[31] Al-Khabbaz A K, Al-Shammari K F, Abdulaziz H, et al. Periodontal health of children with type 1 diabetes mellitus in Kuwait: a case-control study[J]. Medical Principles & Practice International Journal of the Kuwait University Health Science Centre, 2013, 22(2):144-149.
[32] Mickels N, McManus C, Massaro J, et al. Clinical and microbial evaluation of a histatin-containing mouthrinse in humans with experimental gingivitis[J]. J Clin periodontol, 2001, 28(5): 404-410.
[33] Beaumont P E, Mchugh B, Gwyer F E, et al. Cathelicidin host defence peptide augments clearance of pulmonary Pseudomonas aeruginosa infection by its influence on neutrophil function in vivo[J]. Plos One, 2014, 9(6):e99029-e99029.
[34] Horibe K, Nakamichi Y, Uehara S, et al. Roles of cathelicidin-related antimicrobial peptide in murine osteoclastogenesis[J].Immunology,2013,140(3):344-351.
[35] Rosenfeld Y, Papo N, Shai Y. Endotoxin (Lipopolysaccharide) Neutralization by Innate Immunity Host-Defense Peptides PEPTIDE PROPERTIES AND PLAUSIBLE MODES OF ACTION[J]. J Biologi Chemi,2006,281(3):1636-1643.
[36] Scott M G, Vreugdenhil A E, Buurman W A, et al. Cutting edge: cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein[J]. J Immunol,2000,164(2):549-553.
[37] Tew G N, Liu D, Chen B, et al. De novo design of biomimetic antimicrobial polymers[J]. Proceedings of the National Academy of Sciences, 2002, 99(8): 5110-5114.
[38] 王宏军,王金莉,王 乐,等. 附子经口急性毒性试验研究[J]. 农业科学与技术(英文版), 2013, 14(3):530-532.
[39] 侯宝杰,吴志鸿,徐卫鸿, 等. 医用生物蛋白胶的兔眼刺激试验[J]. 眼科研究, 2010, 28(11): 1096-1096.
[40] 陈 雪,林 莉.抗菌肽RISE—AP12对牙龈卟啉单胞菌生长抑制作用研究[J]. 中国实用口腔科杂志, 2014, 7(4):217-220.